Regional outcomes of severe acute respiratory syndrome coronavirus 2 infection in hospitalised patients with haematological malignancy. (13th July 2020)

• Record Type: Journal Article
• Authors: Booth, Stephen; Willan, John; Wong, Henna; Khan, Dalia; Farnell, Rachel; Hunter, Alicia; Eyre, Toby; Katz, Harley; Dungarwalla, Moez; Chen, Lucia; Browning, Joe; Polzella, Paolo; Gray, Nicola; Neelakantan, Pratap; Dhillon, Elissa K.; Dutton, David; Sternberg, Alex; Prideaux, Steven; Collins, Graham P.; Peniket, Andy
• Is Part Of: European journal of haematology. Volume 105:Number 4(2020)
• Page Start: 476
• Page End: 483
• Publication Date: 2020-07-13
• Subjects: haematological malignancy -- SARS‐CoV‐2; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; Blood -- Periodicals; 616.15005
• DOI: 10.1111/ejh.13469
• Languages: English
• ISSNs: 0902-4441

Abstract

Abstract: Objectives: We sought to characterise the outcomes of patients with haematological malignancy and severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection in hospital in our regional network of 7 hospitals. Methods: Consecutive hospitalised patients with haematological malignancy and SARS‐CoV‐2 infection were identified from 01/03/2020 to 06/05/2020. Outcomes were categorised as death, resolved or ongoing. The primary outcome was preliminary case fatality rate (pCFR), defined as the number of cases resulting in death as a proportion of all diagnosed cases. Analysis was primarily descriptive. Results: 66 Patients were included, overall pCFR was 51.5%. Patients ≥ 70 years accounted for the majority of hospitalised cases (42, 63%) and fatalities (25, 74%). Mortality was similar between females (52%) and males (51%). Immunosuppressive or cytotoxic treatment within 3 months of the diagnosis of SARS‐CoV‐2 infection was associated with a significantly higher pCFR of 70%, compared with 28% in those not on active treatment ( P = .0013, 2 proportions z test). Conclusions: Mortality rates in patients with haematological malignancy and SARS‐CoV‐2 infection in hospital are high supporting measures to minimise the risk of infection in this population.